Kymera Therapeutics, Inc. (KYMR)
| Market Cap | 6.86B |
| Revenue (ttm) | 39.21M |
| Net Income (ttm) | -311.35M |
| Shares Out | 81.64M |
| EPS (ttm) | -3.69 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 460,993 |
| Open | 87.90 |
| Previous Close | 86.68 |
| Day's Range | 83.99 - 87.90 |
| 52-Week Range | 28.06 - 103.00 |
| Beta | 2.29 |
| Analysts | Strong Buy |
| Price Target | 107.72 (+28.22%) |
| Earnings Date | Apr 30, 2026 |
About KYMR
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid... [Read more]
Financial Performance
In 2025, Kymera Therapeutics's revenue was $39.21 million, a decrease of -16.70% compared to the previous year's $47.07 million. Losses were -$311.35 million, 39.1% more than in 2024.
Financial StatementsAnalyst Forecast
According to 26 analysts, the average rating for KYMR stock is "Strong Buy." The 12-month stock price target is $107.72, which is an increase of 28.22% from the latest price.
News
Kymera Therapeutics to Report First Quarter 2026 Financial Results on April 30, 2026
WATERTOWN, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicine...
Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Moderate to Severe Asthma
KT-621 BREADTH Phase 2b asthma trial ongoing, with data expected to be reported in late 2027 KT-621 BROADEN2 Phase 2b atopic dermatitis (AD) trial ongoing, with data expected by mid-2027 Fast Track de...
Kymera Therapeutics Presents KT-621 BroADen Data in Late-Breaking Research Session at the American Academy of Dermatology (AAD) Annual Meeting
Featured presentation highlights positive BroADen Phase 1b atopic dermatitis trial results supporting KT-621's compelling oral profile
Kymera Therapeutics Transcript: Barclays 28th Annual Global Healthcare Conference
The company is advancing a pipeline of oral immunology therapies, with STAT6 and IRF5 as lead programs targeting large unmet needs. Phase II trials in atopic dermatitis and asthma are underway, and the company is well-funded to pursue broad clinical development independently.
Kymera Therapeutics Transcript: Leerink Global Healthcare Conference 2026
The conference highlighted advances in targeted protein degradation, with KT-621 showing robust efficacy and safety in early trials for AD and asthma, and strong interest from the medical community. IRF5 is prioritized for lupus, with additional pipeline programs expected to be announced later this year.
Kymera Therapeutics Announces Late-Breaking Oral Presentation of KT-621 Phase 1b Data at the American Academy of Dermatology (AAD) Annual Meeting
WATERTOWN, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicine...
Kymera Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
Two global phase 2B studies for KT-621 in AD and asthma are underway, with key data expected next year. STAT6 degradation shows rapid, robust efficacy comparable to leading biologics, while a new IRF5 degrader targets lupus and related diseases. Combination therapy strategies and further clinical milestones are anticipated.
Kymera Therapeutics Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
Focused on IMiD and protein degradation, the pipeline features promising STAT6 and IRF5 programs, with phase IIb data for AD and asthma expected in 2027. Strong clinical and safety results, a large untapped market, and robust financials position the company for significant growth.
Kymera Therapeutics Earnings Call Transcript: Q4 2025
2025 saw major clinical and financial milestones, including strong KT-621 and KT-579 progress, $1.6B year-end cash, and expanded partnerships. KT-621 phase IIb data in AD and asthma expected in 2027, with KT-579 advancing in lupus.
Kymera Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
WATERTOWN, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines...
Kymera Therapeutics Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026
The discussion highlighted the potential for oral therapies to transform the Type 2 disease market, with KT-621 showing promising safety and efficacy data in early trials. The company is focused on expanding market reach, addressing unmet needs, and advancing a robust pipeline with strong scientific validation.
Kymera Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference
The company is advancing a pipeline of oral degraders targeting immune-inflammatory diseases, with KT-621 showing robust efficacy and safety in AD and asthma. Strong clinical and preclinical data support expansion into multiple indications, aiming to transform patient access and outcomes.
Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs
KT-621 BROADEN2 Phase 2b trial in AD ongoing, with data expected by mid-2027 KT-621 BREADTH Phase 2b trial in asthma initiated, with data expected in late-2027 KT-579 Phase 1 HV clinical trial expecte...
Kymera Therapeutics Announces Closing of Upsized $602 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
WATERTOWN, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines...
Kymera Therapeutics Announces Proposed Public Offering
WATERTOWN, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines...
This Drugmaker's Stock Is Soaring Over 40% Monday
Kymera Therapeutics (KYMR) shares surged over 40% to an all-time high Monday afternooon after the drugmaker reported positive results from an early test of an oral anti-inflammatory drug.
Kymera Therapeutics Transcript: Study Result
KT-621, an oral STAT6 degrader, showed deep target engagement, robust biomarker and clinical improvements, and a favorable safety profile in moderate to severe atopic dermatitis patients, with effects comparable or superior to dupilumab. Benefits extended to comorbid asthma and allergic rhinitis, supporting advancement into phase II-B trials and broader Type 2 disease indications.
Kymera Therapeutics Stock Soars 30%. Why Investors Are Excited About Its Anti-Inflammatory Drug.
The biopharma company is counting on KT-621 to treat patients with Type 2 inflammatory diseases.
Kymera Therapeutics Announces Positive Results from BroADen Phase 1b Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader, in Patients with Moderate to Severe Atopic Dermatitis
KT-621 achieved deep STAT6 degradation across both the 100 mg and 200 mg dose groups tested, with median reductions of 94% and 98% in skin and blood, respectively, demonstrating strong translation fro...
Kymera Therapeutics to Announce KT-621 BroADen Phase 1b Atopic Dermatitis Trial Results on December 8, 2025
Company to host video conference call and webcast at 8:00 a.m. ET on Monday, December 8, 2025 WATERTOWN, Mass.
Kymera Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference
The company is advancing its immunology pipeline, with the STAT6 program entering Phase 2b and data from Phase 1b to be disclosed soon. The IRF5 program is set to begin Phase I trials early next year, targeting high degradation levels for efficacy in autoimmune diseases.
Kymera Therapeutics Transcript: Citi Annual Global Healthcare Conference 2025
The company is advancing its STAT6 and IRF5 programs in immunology, aiming for oral therapies with biologic-like efficacy. Phase II-B studies in atopic dermatitis and asthma are underway, with a strong focus on rapid development, broad patient access, and leveraging AI for efficiency.
Kymera Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference
The company is advancing oral protein degraders in immunology, with KT-621 in phase II-B for atopic dermatitis and asthma, and KT-579 targeting IRF5 entering the clinic next year. Strong partnerships, robust cash position, and a pipeline of novel programs support growth into 2028.
Kymera Therapeutics Announces First Patient Dosed in BROADEN2 Phase 2b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader
Data from the KT-621 BROADEN2 Phase 2b AD patient trial expected to be reported by mid-2027 KT-621 BREADTH Phase 2b trial in asthma on track to initiate in 1Q26 Completed dosing in KT-621 BroADen Phas...
Kymera Therapeutics to Participate in Upcoming December Investor Conferences
WATERTOWN, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines...